Efficacy and safety of secukinumab in moderate to severe plaque psoriasis

被引：0
|
作者：
Aparicio Rubio, Celia [1 ]
Monteagudo Santolaya, Emilio [1 ]
Cornejo Uixeda, Silvia [1 ]
Prieto Castello, Manuel [1 ]
Antonino de la Camara, Gonzalo [1 ]
Quintana Vergara, Belen [1 ]
Sanchez Alcaraz, Agustin [1 ]
机构：
[1] Hosp Univ Ribera, Alzira, Spain
来源：
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY | 2018年 / 40卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PT019
引用
收藏
页码：299 / 299
页数：1
相关论文
共 50 条
  • [21] Secukinumab demonstrates sustained efficacy in moderate to severe plaque psoriasis across disease severity subgroups
    Spelman, L.
    Blauvelt, A.
    Loffler, J.
    Papavassilis, C.
    Fox, T.
    [J]. AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2016, 57 : 74 - 74
  • [22] Secukinumab demonstrates sustained efficacy in moderate to severe plaque psoriasis across disease severity subgroups
    Spelman, Lynda
    Blauvelt, Andrew
    Loeffler, Juergen
    Papavassilis, Charis
    Fox, Todd
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB248 - AB248
  • [23] Comparative efficacy of secukinumab against adalimumab and infliximab in patients with moderate-to-severe plaque psoriasis
    Pan, Ran
    Wang, Xiaolun
    Shu, Min
    Das, Jaydeep
    Kalra, Manik
    Wang, Zhidong
    [J]. CHINESE MEDICAL JOURNAL, 2022, 135 (01) : 11 - 19
  • [24] Real world data with secukinumab for moderate-to-severe plaque psoriasis: Evaluation of safety, efficacy and drug survival in 50 patients
    Gkini, Maria-Angeliki
    Bewley, Anthony
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB114 - AB114
  • [25] Clinical and economic review of secukinumab for moderate-to-severe plaque psoriasis
    Wong, Ian T. Y.
    Shojania, Kam
    Dutz, Jan
    Tsao, Nicole W.
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2016, 16 (02) : 153 - 166
  • [26] Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis
    Cai Lin
    Zhang Jian-Zhong
    Yao Xu
    Gu Jun
    Liu Quan-Zhong
    Zheng Min
    Zhang Shi-Fa
    Xu Jin-Hua
    Li Cheng-Xin
    Cheng Hao
    Guo Qing
    Pan Wei-Li
    Li Shen-Qiu
    Li Ruo-Yu
    Guo Zai-Pei
    Song Zhi-Qi
    Li Shan-Shan
    Dong Xiu-Qin
    Wang Linda
    Fu Rong
    Regnault Pascaline
    Charef Pascal
    Mazur Rafal
    Patekar Manmath
    [J]. 中华医学杂志(英文版), 2020, 133 (22) : 2665 - 2673
  • [27] Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis
    Cai, Lin
    Zhang, Jian-Zhong
    Yao, Xu
    Gu, Jun
    Liu, Quan-Zhong
    Zheng, Min
    Zhang, Shi-Fa
    Xu, Jin-Hua
    Li, Cheng-Xin
    Cheng, Hao
    Guo, Qing
    Pan, Wei-Li
    Li, Shen-Qiu
    Li, Ruo-Yu
    Guo, Zai-Pei
    Song, Zhi-Qi
    Li, Shan-Shan
    Dong, Xiu-Qin
    Wang, Linda
    Fu, Rong
    Regnault, Pascaline
    Charef, Pascal
    Mazur, Rafal
    Patekar, Manmath
    [J]. CHINESE MEDICAL JOURNAL, 2020, 133 (22) : 2665 - 2673
  • [28] Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis
    Egeberg, Alexander
    Bryld, Lars Erik
    Skov, Lone
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (01) : 173 - 178
  • [29] Characterization of responder groups to secukinumab treatment in moderate to severe plaque psoriasis
    Pinter, A.
    Gerdes, S.
    Hacker, E.
    Reinhardt, M.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 114 - 115
  • [30] Secukinumab efficacy and safety in subjects with moderate to severe plaque psoriasis: Results from the Judging the efficacy of secUkinumab in patients with psoriasis using autoiNjector: a Clinical Trial evalUating treatment REsults trial (JUNCTURE)
    Blauvelt, Andrew
    Gottlieb, Alice
    Prinz, Jorg
    Pathan, Rashidkhan
    Cooper, Simon
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB185 - AB185
12345